Introduction
Sarcoidosis is a diverse granulomatous disease that can involve multiple organs. Only a minority of these patients show clinical evidence of cardiac involvement, 1 but autopsy studies have found a much higher prevalence. 2 Cardiac sarcoidosis (CS) is the most problematic representation of the disease with high mortality. 3 CS is usually associated with multi-organ disease, but can manifest also as an isolated disease. Isolated CS (iCS) cases in a recent study from Finland amounted to 63%. 4 Usually, cardiac sarcoid involvement is patchy or focal, but can also present as a widespread granulomatous myocarditis. 2, 5 Different phases of this disease from early active to late and inactive end-stage disease can occur in the same myocardium. 6 The diagnosis of CS is difficult. At present, the only definitive method is histological verification from the myocardium. Endomyocardial biopsy (EMB) has a high specificity for CS but, due to the usually patchy representation of the disease in the myocardium, a low sensitivity. 7, 8 no extra-cardiac involvement. 5 Therefore, especially in isolated CS, the diagnosis is often based on clinical manifestations and imaging modalities. After the introduction of gadolinium-enhanced cardiac magnetic resonance imaging (MRI) and 2-[18F]fluoro-2-deoxy-Dglucose positron emission tomography combined with computed tomography (FDG PET-CT), the detection rate of CS has increased significantly. 9 FDG PET-CT is a non-invasive imaging modality which has over the past decade sustained increasing value as a reliable method in the CS diagnostics. Even though widely used, guidelines of the Japanese Ministry of Health and Welfare (JMHW) failed to include this CSdiagnostic method as presented for example by Dubrey et al. 10 The
World Association for Sarcoidosis and Other Granulomatous Disorders included cardiac PET-CT in their 2014 expert consensus recommendations. 11 Numerous studies show good sensitivity and specificity of FDG PET-CT in CS diagnosis, but all are small series as stated by Youssef et al. 12 in their meta-analysis. In addition, the interpretation of FDG PET-CT is based on visual assessment and therefore is quite subjective and very reader-dependent. Blankstein et al. 13 did, however, find low correlation between JMHW criteria and cardiac PET results. Since FDG is a glucose analogue, it is sensitive for inflammatory processes but not specific. 14 Furthermore, the myocardium uses glucose when available as an energy source and hence significant physiological FDG uptake also occurs in the heart. 15 To describe myocardial inflammation due to CS, a reader-independent method would be of significant value. Tahara et al. 16 introduced heterogeneity of the myocardial FDG uptake [coefficient of variation (CoV)] to be a specific marker of CS. Although the study population was small, their CoV results were encouraging and suggestive of clinical value in addition to visual assessment. The aim of this study was to determinate the diagnostic accuracy of FDG PET-CT CoV in patients with suspected CS. We analysed initial PET-CT's of all patients suspected of CS at our institution between 2007 and 2013.
Methods Patients
All patients referred to PET for suspected CS from beginning of 2007 to the end of 2013 were included in the study. The study was approved by the Helsinki University Hospital Institutional Review Board, and waived the need to obtain informed consent. PET-CT was included in the workup of patients suspected for having CS combined with resting myocardial perfusion imaging in 2007. All together 271 consecutive patients were included in the study. A flowchart of patient selection is presented in Figure 1 . Eight patients were excluded from further analysis due to lack of sufficient clinical data in our medical records, these patients were referred to our hospital from another hospital in Finland. In three patients, the visual assessment of PET-CT and myocardial perfusion data was not possible as the data were not obtainable from our systems any more. In one patient there was no record on the possible EMB and in one patient no knowledge of possible FDG positive lymph nodes. Thirty-two patients had steroid treatment at the time of their first PET scan and were therefore excluded from the study. The final diagnosis of each of the remaining 231 patient was obtained from the electronic medical records in our institution. In our institution, the diagnosis of CS has been based on clinical symptoms and different imaging modalities combined with histological verification of sarcoidosis either in the myocardium or extra-cardiac organs. This is in line with the recent statement from HRS. 17 . Patient's symptoms at onset were recorded from the patient files. If EMB was taken it was marked as positive or non-diagnostic for CS. Patients were categorized into five groups according to their diagnosis: patients with CS as Group 1, patients with cardiomyopathy (CM) (dilating or of unknown origin) as Group 2, patients with giant cell myocarditis (GCM) Group 3, patients with a conductive heart disease (CHD) Group 4 and patients with cardiac symptoms but without a diagnosis of cardiac disease were Group 5. If a CS patient did not have any signs of extracardiac sarcoidosis, including FDG positive mediastinal lymph nodes, either in their previous medical history or in their FDG PET-CT, they were considered to have iCS. If a CS patient had FDG positive mediastinal lymph nodes, the patient was subcategorized as having CS with lymph node involvement.
In order to compare our cardiac patients with patients without cardiac disease, 30 oncological patients were selected as a control group. Of these, 9 patients had lymphoma, 6 lung cancer, 6 gynaecological cancer, 4 head and neck cancer, 2 sigma cancer and 1 penile, 1 pancreatic cancer and 1 patient had a suspicion of a paraneoplastic disease. Inclusion criteria for these control patients were as follows: age between 16 and 80 years, no previous history of myocardial disease, no suspicion of infectious disease, no suspicion of a mediastinal tumour and no previous chemotherapy or radiation therapy to the thorax.
Methods

PET-CT
Patients were advised to fast for at least 12 h prior to the imaging. The control group had an oncological PET-CT, so they had only 6 h fasting. A high-fat low carbohydrate diet prior to cardiac PET-CT was applied in our institution after 2013, so there were no dietary preparations before the patients PET CT. Blood glucose level was controlled, and if it was <7 mmol/l the study was performed. After an intravenous injection of FDG (average 300 MBq), patients rested for 60 min in a semi-darkened, quiet room. Images were acquired with a Gemini PET-CT scanner (Philips Inc, USA). First a CT surview (30 mA, 120 kVp) was obtained and patients were scanned from the base of the skull to mid-thigh (50 mA, 120 kVp). PET emission images were then acquired (8 cm bed position, 1.5 min per frame). In addition to the whole body scan, a separate scan (35 mAs, 140 kVp) was performed of the cardiac area 1 h (16 cm frame, 10 min) and 3 h (16 cm frame, 15 min) after the injection.
Myocardial perfusion imaging
Within a week from the PET-CT-scan, a 99m Tc-tetrofosmin myocardial perfusion imaging at rest was performed. Sixty minutes after the intravenous administration of 99m Tc-tetrofosmin (500 MBq), the data were acquired using a double-head SPECT gamma camera equipped with lowenergy, high-resolution collimators (eCam and Symbia by Siemens Healthineers, Erlangen, Germany or Brightview by Philips, USA). A total of 64 (3 ) projection images were obtained over a 180
, 30 s per view. The imaging matrix used was 128 Â 128. Left ventricular ejection fraction was not included in this study as it seems not to associate with the heterogeneity of myocardial FDG uptake. 16 
Image analysis
Comparison of the PET-CT and myocardial perfusion images was done with ECtool box software (Emory). All images were interpreted by an experienced nuclear medicine physician qualified with multimodality imaging. The myocardial perfusion was compared with the FDG uptake in the left ventricle from standard short and long axis images. Based on visual interpretation, patients were divided into seven categories according to the classification described by Blankstein et al. 13 This was slightly modified by adding an eight category representing fibrotic myocardium, which can be associated with final stage disease. 18 The categories were then divided into three groups based on the assumed clinical relevance; categories 1-2 were considered normal without cardiac involvement (Group V1), categories 3-4 equivocal (V2) and 5-8 (V3) positive for cardiac inflammatory process. The visual classification criteria are presented in Table 1 . All PET-CT studies were evaluated for FDG positive lymph nodes and were classified as positive or negative accordingly. The study was considered positive for lymph node involvement if there was clearly abnormal FDG uptake in lymph nodes. Possible abnormal FDG uptake in other organs was recorded as well.
We used the Carimas V R software package developed at the Turku PET Centre for quantitation of cardiac PET studies to measure the FDG uptake values of all of the 17 segments according to the classification of the American Heart Association. 19 The heterogeneity of the myocardial FDG uptake was assessed according to the method previously described by Tahara et al. 16 CoV of the myocardial FDG uptake was calculated by dividing the standard deviation (SD) of SUVmax by the average SUVmax.
Statistical analysis
Baseline variables and patient characteristics appear as means, SD and range except CoV, which is presented as median as the CoV data are skewed. All statistical analyses were performed with SPSS statistical software version 22.0 (NY, USA). We compared the CoV's of CS patients to those without CS and controls with an independent samples t-test and the CoV's of patients in all diagnostic groups and further, in different visual interpretation groups with one-way analysis of variance and Bonferroni analysis. Patients with CS and positive lymph nodes were correlated to those with CS without lymph node affision with an independent samples t-test. CoV was skewed to the left, so a logarithmic transformation was made but all data are presented as crude. All other data were normally distributed.
Results
Clinical characteristics of the patients are presented in Table 2 . or right bundle branch block, 3 other arrhythmias, 1 chest pain, 1 conduction disorder and 1 elevated troponin T). Heterogeneity of cardiac FDG uptake was significantly higher in the CS group compared with the nCS group (0.253 ± 0.102 vs. 0.195 ± 0.091, P < 0.001) and with the control group (0.140 ± 0.046, P < 0.001). When compared with the control group, nCS patients had a higher CoV (P = 0.005) (Figure 2) . Examples of myocardial FDG distribution and CoV of CS, nCS and control patients are presented in Figure 3 . With the Youden index of maximized sum of sensitivity and specificity, 20 we found a cut-off value of 0.184 for CS to be the most accurate discriminator between CS and nCS groups, with 75.0% sensitivity and 51.4% specificity. With this cut-off value, an AUC of 67.1% was produced from the receiver operating characteristic (ROC) curve. Separating CS patients from controls, a cut-off value of 0.191 for CoV was found to be most accurate with 68.8% sensitivity and 93.3% specificity. The ROC curve produced an AUC of 86.0% with this cut-off value ( Figure 4) . If a CS patient had FDG positive mediastinal lymph nodes, the heterogeneity of the myocardial FDG uptake was higher than in those CS patients who did not have lymph node involvement (0.282 ± 0.107 vs. 0.208 ± 0.075; P 0.016). CoV was not significantly different between CS and iCS (0.268 ± 0.106 vs. 0.212 ± 0.080, P 0.091) patients. Between male and female patients, no significant difference was found in CoV in CS or nCS patients.
In the CS group significantly more patients were visually categorized in Group 3 (representing CS) than in the nCS group. Visual analysis detected CS with a sensitivity of 48.9% and specificity of 51.1% and an accuracy of 71.9%. In Group 3, CS patients had significantly higher CoV than nCS patients ( Table 3) 
Discussion
To our knowledge, this is the largest study on consecutive patients with suspected CS thus far, and its most important finding is that heterogeneity of myocardial glucose uptake discriminated CS from non-CS patients better than did visual analysis with a sensitivity of 75.0% vs. 48.9%, respectively. In addition, the heterogeneity of myocardial FDG uptake presented as CoV was significantly higher in CS patients than in those patients with cardiac symptoms but without CS (0.253 vs. 0.195, P < 0.001) and also than in the oncological control patients without heart disease (0.253 vs. 0.140, P < 0.001).
Our data support the findings of a much smaller series from Tahara et al., 16 in which CoV as a marker of the heterogeneity of myocardial FDG uptake had good accuracy to detect CS patients, compared to figures for control patients without cardiac disease. Further, it separated CS patients from patients with other cardiac disease with fair accuracy and could therefore be used in clinical settings as a reliable method to detect CS. The cut-off value of CoV for the best accuracy in diagnosing CS was similar to that they found, but with much lower sensitivity (75% vs. 100%) and specificity (51.4% vs. 97%). This may be due to the smaller and obviously more selected patient population compared to our unselected consecutive patient group. In a recent study with FDG PET-CT from 62 patients, of which 26 with CS, Tezuka et al. 21 found best accuracy with a cut-off CoV value of 0.22 (sensitivity 92%, specificity 81%).
In addition, we found that in CS patients with FDG-positive lymph nodes, myocardial FDG uptake heterogeneity is significantly higher than in those without lymph node involvement (P = 0.010). No data exist on severity of cardiac inflammation based on extra-cardiac findings of sarcoidosis, but our data suggest that inflammation in patients with active lymph nodes or extra cardiac active sites might be more profound than in those with only cardiac involvement. Also, CS patients with more severe symptoms, notably AVB, could have a more heterogenic myocardial FDG uptake compared to patients with moderate symptoms.
In a recent prospective study by Yokoyama et al., 22 myocardial FDG uptake expressed as standardized uptake value (SUV) was significantly higher in 37 CS patients compared with 55 non-CS patients.
With a SUVmax cut-off value 4.0, they found a sensitivity of 97% and specificity of 84% for detecting CS. We did not include SUV values in our analysis as these were not automatically obtainable from the PET-CT data of the first patients in our population. Since histological diagnosis from the myocardium is available in only a minority of suspected CS patients, 7 demand is high for a noninvasive diagnostic methods to support the clinical suspicion of CS. FDG PET-CT is popular in this setting along with cardiac MRI, but in the diagnosis of CS many issues still exist concerning the clinical value of this modality. Though many studies address the sensitivity and specificity of FDG PET-CT for CS, these studies have had a relatively small sample size that limits the generalizability of their results. Additionally, most of the studies are based only on visual assessment of the FDG PET-CT, which is highly reader dependent. In our study, visual assessment had poor sensitivity in detecting CS, comparable to coin toss. Accordingly, Blankstein et al. 13 found poor correlation between cardiac PET results and JMHW criteria, most obviously due to the low sensitivity of the JMHW criteria. A crucial factor for the diagnosis is therefore the experience of the reader in interpreting cardiac FDG PET-CT. A semi-quantitative method such as CoV, reflecting the heterogeneity of myocardial FDG uptake and the severity of the inflammatory process, would be of great clinical value, and it may improve the performance of the reader in detecting CS. In our study, with a CoV cut-off value of 0.184 suggesting CS, 67% of the visually false-negatively assessed CS patients could be identified as CS. CS diagnosis is especially difficult when there are no signs of extracardial disease and histological verification is only available from the myocardium. Tezuka et al. 21 found similar myocardial FDG uptake heterogeneity represented as CoV in CS and isolated CS, and CoV's in both these groups to be significantly higher than in sarcoidosis without CS and control group. This is supported by our findings, as there was no significant difference in CoV between CS patients with or without extracardiac disease. Therefore, it seems that FDG PET-CT with CoV analysis could bring major additional information to the diagnosis of iCS. We suggest that this method be used in conjunction with visual assessment because it is highly operator independent, it improves consistency between physicians and thus improves the accuracy of FDG PET-CT. Combining measurement of CoV to visual analysis significantly improves the diagnostic accuracy of FDG PET-CT for CS.
Limitations
A high fat, low carbohydrate diet before a cardiac PET-CT has been widely accepted as a routine protocol, although no consensus on the protocol itself has been established. In this study, there was no dietary preparation, apart from prolonged fasting, in our institution before the PET-CT study up till 2013. This may have had an impact on the visual assessment of the PET study and the poor correlation between visual assessment and CoV results. Visual assessment was done by one experienced NM physician only, so no comparison or confirmation of the results was done. On the other hand, this enabled the consistent interpretation of the PET-CT. We did not include SUV values, as these were not obtainable from all patients. SUV could be another useful variable to take into consideration in the diagnosis of CS.
As a rule, patients included in the study were in the early stages of the suspected disease without a diagnosis and therefore were not on immunosuppressive therapy at the time of the PET-CT. However, this could not be verified in a few patients because the medical data were not complete.
Conclusion
The increased heterogeneity of myocardial FDG uptake is a strong indicator of CS. It provides a reader independent, semi-quantitative method to improve the accuracy of PET-CT in the diagnosis of CS and should be used together with a visual analysis. It might also be a marker of disease activity, but this needs to be confirmed in prospective studies, as well as to verify the prognostic value of CoV in CS patients.
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